Fully human CD19-specific chimeric antigen receptors for T-cell therapy

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA

(2015) Donald O'Rourke et al.   NEURO-ONCOLOGY

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity

(2015) De-Gang Song et al.   Oncotarget

Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types

(2015) Laetitia E. Lamberts et al.   Oncotarget

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

(2015) M. J. Frigault et al.   Cancer Immunology Research

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

Safety of Targeting ROR1 in Primates with Chimeric Antigen Receptor-Modified T Cells

(2014) C. Berger et al.   Cancer Immunology Research

Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

(2013) M. Hudecek et al.   CLINICAL CANCER RESEARCH

Precision mapping of the human O-GalNAc glycoproteome through SimpleCell technology

(2013) Catharina Steentoft et al.   EMBO JOURNAL

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

(2013) Michael C. Jensen et al.   IMMUNOLOGICAL REVIEWS

A CD19/Fc fusion protein for detection of anti-CD19 chimeric antigen receptors

(2013) Satiro N De Oliveira et al.   Journal of Translational Medicine

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors

(2013) James N. Kochenderfer et al.   Nature Reviews Clinical Oncology

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans

(2013) M. V. Maus et al.   Cancer Immunology Research

CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors

(2013) Vanesa Alonso-Camino et al.   Molecular Therapy-Nucleic Acids

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

(2011) S. Terakura et al.   BLOOD

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells

(2011) X. Wang et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor

(2011) Evripidis Lanitis et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells

(2010) C. H. J. Lamers et al.   BLOOD

A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity

(2009) Y. Zhao et al.   JOURNAL OF IMMUNOLOGY

Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette

(2008) Matthias Leisegang et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11

(2008) Claus Lundegaard et al.   NUCLEIC ACIDS RESEARCH